Tonix Pharmaceuticals Holding is a biotechnology business based in the US. Tonix Pharmaceuticals Holding shares (TNXP) are listed on the NASDAQ and all prices are listed in US Dollars. Tonix Pharmaceuticals Holding employs 117 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.79 |
|---|---|
| 52-week range | $0.77 - $9.81 |
| 50-day moving average | $1.12 |
| 200-day moving average | $2.94 |
| Wall St. target price | $11.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-8.44 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.79 from 2023-09-26
| 1 week (2023-09-20) | -8.14% |
|---|---|
| 1 month (2023-08-25) | -14.13% |
| 3 months (2023-06-27) | -43.97% |
| 6 months (2023-03-27) | 41.07% |
| 1 year (2022-09-27) | 46.30% |
|---|---|
| 2 years (2021-09-27) | 27.42% |
| 3 years (2020-09-25) | 0.848 |
| 5 years (2018-09-27) | 60 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -35.91% |
| Return on equity TTM | -60.97% |
| Profit margin | 0% |
| Book value | $13.05 |
| Market Capitalization | $14.4 million |
TTM: trailing 12 months
We're not expecting Tonix Pharmaceuticals Holding to pay a dividend over the next 12 months.
Tonix Pharmaceuticals Holding's shares were split on a 16:100 basis on 9 May 2023. So if you had owned 100 shares the day before before the split, the next day you'd have owned 16 shares. This wouldn't directly have changed the overall worth of your Tonix Pharmaceuticals Holding shares – just the quantity. However, indirectly, the new 525% higher share price could have impacted the market appetite for Tonix Pharmaceuticals Holding shares which in turn could have impacted Tonix Pharmaceuticals Holding's share price.
Over the last 12 months, Tonix Pharmaceuticals Holding's shares have ranged in value from as little as $0.77 up to $9.8125. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tonix Pharmaceuticals Holding's is 2.2147. This would suggest that Tonix Pharmaceuticals Holding's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tonix Pharmaceuticals Holding Corp. , a clinical-stage biopharmaceutical company, develops therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed to treat autoimmune conditions. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; and TNX-102 SL, a CNS product candidate to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a recombinant protein enzyme to treat cocaine intoxication.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.